급성 흥분 및 공격성 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Acute Agitation and Aggression Treatment Market - Scope of Report

TMR's report on the global acute agitation and aggression treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global acute agitation and aggression treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute agitation and aggression treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute agitation and aggression treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute agitation and aggression treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute agitation and aggression treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute agitation and aggression treatment market.

The report delves into the competitive landscape of the global acute agitation and aggression treatment market. Key players operating in the global acute agitation and aggression treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute agitation and aggression treatment market profiled in this report.

Key Questions Answered in Global acute agitation and aggression treatment Market Report:

• What is the sales/revenue generated by acute agitation and aggression treatment across all regions during the forecast period?
• What are the opportunities in the global acute agitation and aggression treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Acute Agitation and Aggression Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global acute agitation and aggression treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute agitation and aggression treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute agitation and aggression treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Agitation and Aggression Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Treatment Protocol
• 5.2. Key Strategies adopted by Market Players
• 5.3. Mental Health Spendings by Countries
• 5.4. Healthcare Industry Overview
• 5.5. PESTEL Analysis
• 5.6. PORTER's Five Forces Analysis
• 5.7. Pipeline Analysis
• 5.8. Regulatory Scenario Assessment
• 5.9. Reimbursement Scenario by Key Countries
• 5.10. Epidemiology of Acute Agitations and Aggression Disorders
• 5.11. Supply Chain Analysis
• 5.12. Key Industry Events

6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Treatment Approach, 2020-2034
  • 6.3.1. First-Generation Anti-Psychotics:
    • 6.3.1.1. Chlorpromazine
    • 6.3.1.2. Haloperidol
  • 6.3.2. Second-Generation Anti-Psychotics
    • 6.3.2.1. Quetiapine
    • 6.3.2.2. Olanzapine
    • 6.3.2.3. Ziprasidone
  • 6.3.3. Benzodiazepines
    • 6.3.3.1. Lorazepam
    • 6.3.3.2. Midazolam
  • 6.3.4. Alpha-2 Adrenergic Agonist
    • 6.3.4.1. Clonidine
    • 6.3.4.2. Dexmedetomidine
  • 6.3.5. Others
• 6.4. Market Attractiveness Analysis, by Treatment Approach

7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Indication, 2020-2034
  • 7.3.1. Alcohol Withdrawal
  • 7.3.2. Bipolar Disorder
  • 7.3.3. Dementia
  • 7.3.4. Depression
  • 7.3.5. Drug-induced agitation and aggression
  • 7.3.6. Schizophrenia
  • 7.3.7. Others
• 7.4. Market Attractiveness Analysis, by Indication

8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2020-2034
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Treatment Approach, 2020-2034
  • 10.2.1. First-Generation Anti-Psychotics:
    • 10.2.1.1. Chlorpromazine
    • 10.2.1.2. Haloperidol
  • 10.2.2. Second-Generation Anti-Psychotics
    • 10.2.2.1. Quetiapine
    • 10.2.2.2. Olanzapine
    • 10.2.2.3. Ziprasidone
  • 10.2.3. Benzodiazepines
    • 10.2.3.1. Lorazepam
    • 10.2.3.2. Midazolam
  • 10.2.4. Alpha-2 Adrenergic Agonist
    • 10.2.4.1. Clonidine
    • 10.2.4.2. Dexmedetomidine
  • 10.2.5. Others
• 10.3. Market Value Forecast, by Indication, 2020-2034
  • 10.3.1. Alcohol Withdrawal
  • 10.3.2. Bipolar Disorder
  • 10.3.3. Dementia
  • 10.3.4. Depression
  • 10.3.5. Drug-induced agitation and aggression
  • 10.3.6. Schizophrenia
  • 10.3.7. Others
• 10.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast, by Country, 2020-2034
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Treatment Approach
  • 10.6.2. By Indication
  • 10.6.3. By Distribution Channel
  • 10.6.4. By Country

11. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Treatment Approach, 2020-2034
  • 11.2.1. First-Generation Anti-Psychotics:
    • 11.2.1.1. Chlorpromazine
    • 11.2.1.2. Haloperidol
  • 11.2.2. Second-Generation Anti-Psychotics
    • 11.2.2.1. Quetiapine
    • 11.2.2.2. Olanzapine
    • 11.2.2.3. Ziprasidone
  • 11.2.3. Benzodiazepines
    • 11.2.3.1. Lorazepam
    • 11.2.3.2. Midazolam
  • 11.2.4. Alpha-2 Adrenergic Agonist
    • 11.2.4.1. Clonidine
    • 11.2.4.2. Dexmedetomidine
  • 11.2.5. Others
• 11.3. Market Value Forecast, by Indication, 2020-2034
  • 11.3.1. Alcohol Withdrawal
  • 11.3.2. Bipolar Disorder
  • 11.3.3. Dementia
  • 11.3.4. Depression
  • 11.3.5. Drug-induced agitation and aggression
  • 11.3.6. Schizophrenia
  • 11.3.7. Others
• 11.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 11.4.1. Hospital Pharmacies
  • 11.4.2. Retail Pharmacies
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 11.5.1. Germany
  • 11.5.2. UK
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Treatment Approach
  • 11.6.2. By Indication
  • 11.6.3. By Distribution Channel
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Treatment Approach, 2020-2034
  • 12.2.1. First-Generation Anti-Psychotics:
    • 12.2.1.1. Chlorpromazine
    • 12.2.1.2. Haloperidol
  • 12.2.2. Second-Generation Anti-Psychotics
    • 12.2.2.1. Quetiapine
    • 12.2.2.2. Olanzapine
    • 12.2.2.3. Ziprasidone
  • 12.2.3. Benzodiazepines
    • 12.2.3.1. Lorazepam
    • 12.2.3.2. Midazolam
  • 12.2.4. Alpha-2 Adrenergic Agonist
    • 12.2.4.1. Clonidine
    • 12.2.4.2. Dexmedetomidine
    • 12.2.4.3. Guanabenz
  • 12.2.5. Others
• 12.3. Market Value Forecast, by Indication, 2020-2034
  • 12.3.1. Alcohol Withdrawal
  • 12.3.2. Bipolar Disorder
  • 12.3.3. Dementia
  • 12.3.4. Depression
  • 12.3.5. Drug-induced agitation and aggression
  • 12.3.6. Schizophrenia
  • 12.3.7. Others
• 12.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 12.4.1. Hospital Pharmacies
  • 12.4.2. Retail Pharmacies
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & Newzealend
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Treatment Approach
  • 12.6.2. By Indication
  • 12.6.3. By Distribution Channel
  • 12.6.4. By Country/Sub-region

13. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Treatment Approach, 2020-2034
  • 13.2.1. First-Generation Anti-Psychotics:
    • 13.2.1.1. Chlorpromazine
    • 13.2.1.2. Haloperidol
  • 13.2.2. Second-Generation Anti-Psychotics
    • 13.2.2.1. Quetiapine
    • 13.2.2.2. Olanzapine
    • 13.2.2.3. Ziprasidone
  • 13.2.3. Benzodiazepines
    • 13.2.3.1. Lorazepam
    • 13.2.3.2. Midazolam
  • 13.2.4. Alpha-2 Adrenergic Agonist
    • 13.2.4.1. Clonidine
    • 13.2.4.2. Dexmedetomidine
    • 13.2.4.3. Guanabenz
  • 13.2.5. Others
• 13.3. Market Value Forecast, by Indication, 2020-2034
  • 13.3.1. Alcohol Withdrawal
  • 13.3.2. Bipolar Disorder
  • 13.3.3. Dementia
  • 13.3.4. Depression
  • 13.3.5. Drug-induced agitation and aggression
  • 13.3.6. Schizophrenia
  • 13.3.7. Others
• 13.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 13.4.1. Hospital Pharmacies
  • 13.4.2. Retail Pharmacies
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Treatment Approach
  • 13.6.2. By Indication
  • 13.6.3. By Distribution Channel
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Treatment Approach, 2020-2034
  • 14.2.1. First-Generation Anti-Psychotics:
    • 14.2.1.1. Chlorpromazine
    • 14.2.1.2. Haloperidol
  • 14.2.2. Second-Generation Anti-Psychotics
    • 14.2.2.1. Quetiapine
    • 14.2.2.2. Olanzapine
    • 14.2.2.3. Ziprasidone
  • 14.2.3. Benzodiazepines
    • 14.2.3.1. Lorazepam
    • 14.2.3.2. Midazolam
  • 14.2.4. Alpha-2 Adrenergic Agonist
    • 14.2.4.1. Clonidine
    • 14.2.4.2. Dexmedetomidine
    • 14.2.4.3. Guanabenz
  • 14.2.5. Others
• 14.3. Market Value Forecast, by Indication, 2020-2034
  • 14.3.1. Alcohol Withdrawal
  • 14.3.2. Bipolar Disorder
  • 14.3.3. Dementia
  • 14.3.4. Depression
  • 14.3.5. Drug-induced agitation and aggression
  • 14.3.6. Schizophrenia
  • 14.3.7. Others
• 14.4. Market Value Forecast, by Distribution Channel, 2020-2034
  • 14.4.1. Hospital Pharmacies
  • 14.4.2. Retail Pharmacies
  • 14.4.3. Online Pharmacies
• 14.5. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Treatment Approach
  • 14.6.2. By Indication
  • 14.6.3. By Distribution Channel
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis, by Company (2023)
• 15.3. Company Profiles
  • 15.3.1. Eli Lilly and Company
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Pfizer, Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. GlaxoSmithKline
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Johnson & Johnson
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. Teva Pharmaceutical Industries Ltd.
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Amneal Pharmaceuticals LLC
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. F. Hoffmann-La Roche Ltd
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Bausch Health Companies, Inc.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Apotex, Inc.
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments